Based of of what I have been reading, the medtone faced several challenges with regards to fda approval, which the company previously intended to move fowared with, until the decision to switch to the dreamboat was made due to reasons listed next. The fact that this medtone device was 30% less efficent than the dreamboat device, coupled wih the issues they faced as to loading the device, complications with inhaling the medication through medtone vs dreamboat, storing the device, and cleaning the device and manufacterig costs --definately seems to be enough to make the dreamboat switch.
It also makes sense to me, as to why the fda would request more human trials when using 30% less experimental affrezza medication, and a completly different delivery application (dreamboat)., whether it shown on a machiene to be more efective, still lacks human response.

Medtone had similar issues that the previous Exubera bong faced.

Assuming that the most current dreamboat afrezza trials show a success and consistency or superiority with previous results and current fastacting insulins, & the dreamboat proves to be effective of an upgrade as I believe most see it to be, this company should do well post approval especially with marketing the device to doctors and patients, especially when compared to medtone & prior failures (exubera bong).